ReviewJournal of pain research2022
The Burden of Metastatic Cancer-Induced Bone Pain: A Narrative Review.
Review in Journal of pain research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular targets in bone cancer pain: a systematic review of inflammatory cytokines.Journal of molecular medicine (Berlin, Germany) · 2024Pooled it
- Methadone versus other opioids for refractory malignant bone pain: a pilot randomised controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Cancer pain.Nature reviews. Disease primers · 2026Review
- The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain.JCI insight · 2026Article
- Applications of micro/nano drug delivery systems in cancer pain management.Bioactive materials · 2026Review
- Evolving Paradigms in Cancer Pain Management: From Opioid-Centric Care to Multimodal and Personalized Strategies.Cancers · 2026Review
- A Cross-Sectional Study on the Status of Female Lung Cancer Patients With Bone Metastasis With or Without Osteoporosis.Health science reports · 2025Article
- The Relationship Between Radiotherapy-Induced Pain Response Score and Pain Biomarkers TRPV1, β-Endorphin (bEP), Neurotensin (NT), and Orexin A (OXA) in Patients with Bone Metastases.Life (Basel, Switzerland) · 2025Article
- Minimally Invasive Treatment Strategies for Metastatic Disease of the Skeleton: Current Concepts.Current oncology reports · 2025Review
- Advances in Neuroimaging of Breast Cancer Pain: An Overview.Journal of pain research · 2025Review
- Efficacy and Safety of Acupuncture Combined with Conventional Drug Therapy for the Treatment of Cancer-Induced Bone Pain: A Network Meta-Analysis of Randomized Controlled Trials.Journal of pain research · 2025Review
- Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.International journal of cancer · 2024Article
- An Update on Emerging Regenerative Medicine Applications: The Use of Extracellular Vesicles and Exosomes for the Management of Chronic Pain.Current pain and headache reports · 2024Review
- Impacts of radiation therapy on quality of life and pain relief in patients with bone metastases.World journal of orthopedics · 2024Review
- Real-world impact of acupuncture on analgesics and healthcare resource utilization in breast cancer survivors with pain.BMC medicine · 2024Article
- Update on musculoskeletal applications of magnetic resonance-guided focused ultrasound.Skeletal radiology · 2024Review
- Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity.Cell communication and signaling : CCS · 2024Review
- Prolonged Effect of Repetitive Erector Spinae Plane Block in Reducing Thoracic Pain Caused by Lung Cancer.Cureus · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone pain is one of the most common forms of pain reported by cancer patients with metastatic disease. We conducted a review of oncology literature to further understand the epidemiology of and treatment approaches for metastatic cancer-induced bone pain and the effect of treatment of painful bone metastases on the patient's quality of life. Two-thirds of patients with advanced, metastatic, or terminal cancer worldwide experience pain. Cancer pain due to bone metastases is the most common form of pain in patients with advanced disease and has been shown to significantly reduce patients' quality of life. Treatment options for cancer pain due to bone metastases include nonsteroidal anti-inflammatory drugs, palliative radiation, bisphosphonates, denosumab, and opioids. Therapies including palliative radiation and opioids have strong evidence supporting their efficacy treating cancer pain due to bone metastases; other therapies, like bisphosphonates and denosumab, do not. There is sufficient evidence that patients who experience pain relief after radiation therapy have improved quality of life; however, a substantial proportion are nonresponders. For those still requiring pain management, even with available analgesics, many patients are undertreated for cancer pain due to bone metastases, indicating an unmet need. The studies in this review were not designed to determine why cancer pain due to bone metastases was undertreated. Studies specifically addressing cancer pain due to bone metastases, rather than general cancer pain, are limited. Additional research is needed to determine patient preferences and physician attitudes regarding choice of analgesic for moderate to severe cancer pain due to bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.